Preclinical (original) (raw)
Latest News for: preclinical
Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026
Killeen Daily Herald 15 Jun 2026
Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical ....
Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete
The Eagle-Tribune 15 Jun 2026
– ETHY-001 produced complete blockade of autoantibody-mediated TSHR activation across all patient serum samples tested, demonstrating breadth and consistency of effect – ... .
Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of ...
Nasdaq Globe Newswire 15 Jun 2026
– ETHY-001 produced complete blockade of autoantibody-mediated TSHR activation across all patient serum samples tested, demonstrating breadth and consistency of effect – ... .
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
Nasdaq Globe Newswire 15 Jun 2026
OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ...
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model (Telomir Pharmaceuticals Inc)
Public Technologies 15 Jun 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 132472913) .
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026 (Opko Health Inc)
Public Technologies 15 Jun 2026
) אופקו הלת', אינק. OPKO HEALTH, INC. Corporation no. 2279206. Israel Securities Authority Tel Aviv Stock Exchange C002 ( Public ) Reported via MAGNA. 15/06/2026. www.isa.gov.il www.tase.co.il Reference. 2026-02-056447. Immediate Report ... Address.
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model (Form 8-K) (Telomir Pharmaceuticals Inc)
Public Technologies 15 Jun 2026
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model.
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology ...
Nasdaq Globe Newswire 12 Jun 2026
-�JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - ... .
Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor
The Eagle-Tribune 12 Jun 2026
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Recludix ...
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026
The Eagle-Tribune 12 Jun 2026
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - ... .
Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at ...
Nasdaq Globe Newswire 12 Jun 2026
... disease, today announced preclinical data for REX-8756, an oral, potent and selective STAT6 inhibitor, is being presented at two upcoming scientific congresses.
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
Killeen Daily Herald 11 Jun 2026
EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe vaccine ....
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor
The Eagle-Tribune 11 Jun 2026
Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release safety profile compared to the non-capped variant ... .
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety ...
Nasdaq Globe Newswire 11 Jun 2026
Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release safety profile compared to the non-capped variant ... .
Paratus Sciences Presents Preclinical and Translational Data on PS-1001, a First-in-Class
Hastings Tribune 11 Jun 2026
- First-in-human trial of PS-1001 planned to initiate in 2027 - ... .